select-d: Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism: a prospective, randomised, open label, multicentre pilot study

Trial Profile

select-d: Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism: a prospective, randomised, open label, multicentre pilot study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Dalteparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms select-d
  • Most Recent Events

    • 09 Dec 2017 According to an American Society of Hematology media release, data from this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition (2017).
    • 16 May 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2018.
    • 04 Dec 2015 Accural to date is 49% according to the United Kingdom Clinical Research Network Record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top